Keyword: Actelion

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.

Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.

Here is some other vaccine news of note for the week.

Top pharma companies are circling Shire for a potential buy, The Telegraph reports, just as U.S. tax changes are expected to fill M&A war chests.

Now that Republicans in Congress have passed tax reform, the pharma sector could be due for a long-anticipated M&A rebound.

Novartis is hunting for bolt-on deals, but too-high biotech valuations have forced its M&A scouts to eye early-stage assets.